2 Department of Dermatology, School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
3 Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd, 3 Miyahara, Gunma 370-12, Japan
4 La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
Correspondence to: M. Taniguchi
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Keywords: -galactosylceramide, NKT cell receptor, docking modeling
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Crystallographic analysis has indicated that the mouse CD1d (mCD1d) has a deep, narrow and very hydrophobic ligand-binding groove with two pockets denoted A' and F' (17). In fact, the interaction of glycolipids with mCD1d has been demonstrated by biochemical analysis (18,19). It has also been suggested that the two long alkyl chains of the ligand are able to be accommodated in the two hydrophobic pockets (A' and F'), while the hydrophilic head group of the antigen is exposed for recognition by the NKT cell antigen receptor (20).
The analysis of the structureactivity relationship of glycosylceramides strongly suggest that the antigenicity is highly susceptible to the molecular structure of the glycosylceramides (11,2124). Especially important are the 1''- linkage between the sugar and ceramide moieties, the existence of the 2''-OH in the sugar pyranose ring, and the existence of the 3-OH on the sphingosine. Possible binding conformations of
-GalCer analogues with mCD1d are calculated in which active analogues could share important pharmacophoric groups (25) and the seven possible conformations are suggested by the calculation. However, the active conformation could not be determined from the information obtained from the structureactivity relationship study alone.
In the present study, the molecular basis of the binding and recognition of glycolipids with mCD1d is addressed by computer modeling and by functional assay. The docking modeling and functional study using a series of mutant mCD1d-transfected cells suggest that the polar amino acid residues located over the F' pocket, including Arg79, Asp80 and Glu83 in the 1-helix, and Asp153 in the
2-helix of mCD1d, and a backbone carbonyl group (Val149) on the
2-helix are essential for the efficient activation of V
14 NKT cells.
![]() |
Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Glycolipids
The -GalCer (KRN7000) was prepared in the Pharmaceutical Research Laboratories, Kirin Brewery (Gunma, Japan). Antigen stock solution (100 µg/ml) was stored in DMSO at 4°C.
Computer modeling
Software.
The modeling study was aided by the SYBYL software package (Tripos Associates, St Louis, MO). SYBYL Programming Language was utilized for programming specific procedures developed in this study.
Step 1: ligand binding sites of mCD1d.
In our previous study we have shown that the long alkyl chains of -GalCer (AGL517) and
-glucosylcceramide (
-GlcCer) (AGL563) (Fig. 1A
) would bind to the inside the A' and F' pockets via hydrophobic interaction (11). Although most of the amino acid residues near the binding groove are hydrophobic, His68, Ser76, Arg79, Asp80, Glu83, Lys148, Asp153, Thr156, Thr159, Asp166 and Thr167 are polar residues that might interact by hydrogen bonding with the amide or hydroxyl groups of
-GalCer. Most of these residues are located near the center of the binding helices except His68, Lys148 and Asp166. Thus we chose the side chains of Ser76, Arg79, Asp80, Glu83, Asp153, Thr156, Thr159 and Thr167 as candidate hydrogen bond donor/acceptor sites, several of which interact with hydrogen acceptor/donor atoms of ligand molecules (Fig. 1B
). Distances between pairs of heteroatoms in the side chains of the above-mentioned amino acid residues were calculated. The accuracy factor (or grid size) of the distance was set to 0.8 Å, i.e. if a distance was in the range of 0.00.8 Å, it was considered to be 0.4 Å, and a value 1.2 Å was assigned for a distance between 0.8 and 1.6 Å.
|
|
Step 4: superimposition of AGL517 and AGL563 in the frame of the mCD1d structure.
In the previous step, 20 docking models were calculated. Using mCD1d as the frame of reference, the docked models of AGL517 and AGL563 were compared for pharmacophore overlap. The goodness of overlap was measured by r.m.s. fit value for the 2''-, 4''- and 3-OH groups. Extending the alkyl chains of AGL517 produced the docking model of -GalCer (KRN7000) (m = 24, n=13). Finally, structure optimization was applied exclusively to the extended carbon chains.
Mutagenesis of mCD1d and their transfectants
The mCD1d cDNA was established by L. Brossay and M. Kronenberg (26), and was in a pHßAprmCD1.1neo plasmid. For mutagenesis, the insert mCD1d cDNA was ligated with a cloning vector pGEM-11zf using unique SalI and BamHI sites (P2371; Promega Madison, WI). Mutant mCD1d cDNAs were obtained with a Gene Editor in vitro site-directed mutagenesis system (Q9280; Promega) using mutagenic oligonucleotides as follows: R74A: 5'-GTTTCAAGTCTATGCAGTCAGCTTTACCAGGG-3'; V75A, 5'-CAAGTCTATCGAGCCAGCTTTACCAGGGAC-3';S76A, 5'-GTCTATCGAGTCGCCTTTACCAGGGACATAC-3'; F77A, 5'-CTATCGAGTCAGCGCTACCAGGGACATACAGG-3'; T78A, 5'-CGAGTCAGCTTTGCCAGGGACATACAGGAATT-3'; R79A, 5'-CGAGTCAGCTTTACCGCGGACATACAGGAATTAGTC-3'; D80A, 5'-CTTTACCAGGGCCATACAGGAATTAGTCAA-3'; I81A, 5'-GCTTTACCAGGGACGCACAGGAATTAGTCAAAATG-3'; Q82A, 5'-CCAGGGACATAGCGGAATTAGTCAAAATGATG-3'; E83A, 5'-GGACATACAGGCATTAGTCAAAATGATGTCAC-3'; L84A, 5'-GACATACAGGAAGCAGTCAAAATGATGTCACC-3'; V85A, 5'-CATACAGGAATTAGCCAAAATGATGTCACCTAA-3'; K86A, 5'-CAGGAATTAGTCGCAATGATGTCACCTAAAGAAG-3';K148A,5'-GTTAGACTTGCCCATCGCAGTGCTCAACGCTGATC-3';N151A, 5'-CATCAAAGTGCTCGCCGCTGATCAAGGGACA-AG-3'; D153A,5'-GCTCAACGCTGCTCAAGGGACAAGTGCAAC-3'; Q154A, 5'-GCTCAACGCTGATGCAGGGACAAGTGCAACCG-3'; G155A, 5'-CAACGCTGATCAAGCGACAAGTGCAACCGTGC-3'; D166A, 5'-GCTCCTGAATGCCACCTGCCCCCTAT-3'.
The mutant mCD1d cDNAs were inserted into the expression vector pHßAprneo, after the alanine substitution was confirmed by DNA sequencing. Transfection was performed using RMA-S cells lacking TAP-1 as described previously (26). The expression of wild-type and mutant mCD1d was detected by staining with anti-mCD1d antibodies (1B1 and 1H1; PharMingen, San Diego, CA).
V14 NKT cell lines and clones
V14 NKT cell lines were generated as described previously (27) with a slight modification. In brief, spleen cells (1x105/well) from V
14 NKT mice were cultured in anti-CD3 mAb (145-2C11, 100 µg/ml)-coated 96-well round-bottomed plates (#3077; Falcon, Franklin Lakes, NJ) in the presence of 100 U/ml of recombinant mouse IL-4 for 3 days and then expanded in six-well plates (#3516; Costar, Corning, NY) with 100 U/ml of recombinant mouse IL-4 for 2 days. The cells were then transferred and cultured with 30 U/ml of recombinant mouse IL-4 for another 2 days in new plates. A CD1d-restricted phosphatidylinositol-reactive V
14 NKT cell clone, 24.8A1 (28), was kindly provided by Drs M. Brenner and S. Behar (Harvard Medical School, Boston).
Measurement of cytokine production
V14 NKT cell lines or the 24.8A1 V
14 NKT cell clone were co-cultured with wild-type or mutant mCD1d expressing RMA-S cells or non-transfected parental RMA-S cells, which had been preincubated with
-GalCer (100 ng/ml) for 12 h, in RPMI 1640 supplemented with 10% FCS, kanamycin (100 mg/ml), 2 mM L-glutamine and 50 mM 2-mercaptoethanol in 96-well round-bottomed culture plates under humidified 5% CO2 at 37°C. The amounts of IFN-
or IL-2 in the culture supernatants were assessed using a standard sandwich ELISA according to the manufacturer's protocol (PharMingen, San Diego, CA).
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
To identify a possible hydrogen-bonding interaction between mCD1d and -GalCer, computer-aided molecular modeling was carried out. The modeling study utilized the results from the structureactivity relationship study carried out previously (25). In the present study, we calculated the putative active conformations for
-GalCer (AGL517) and
-GlcCer (AGL563) (Fig. 1 A
) by assuming that these active analogues bind to a receptor molecule (mCD1d) with a common geometric arrangement of the 2''-OH on the sugar, the 3-OH on the sphingosine and the 4''-OH on the sugar, which represents the orientation of the sugar ring. It was found that there are seven possible ways for the active analogues to arrange their hydroxyl groups in space (25).
The docking models were then searched using the following assumptions:
Under the above assumptions, we first selected several hydrophilic amino acid residues that locate near the binding groove of mCD1d (Fig. 1B). Some of the heteroatoms in the side chains of these hydrophilic residues would interact with
-monoglycosylceramides by forming hydrogen bonds. These atoms were considered to be possible hydrogen-bonding sites of the receptor (Assumptions 1 and 2). On the other hand, dummy atoms were added to the heteroatoms of
-monoglycosylceramides. These dummy atoms represented hydrogen-bonding partner sites on the mCD1d (Fig. 2A and B
; Assumption 1). By fixing the conformation of the
-monoglycosylceramides in one of the seven possibilities (Assumption 3), the bonds indicated in Fig. 2
(B) were systematically rotated to map the possible hydrogen-bonding sites. Mapping of the possible hydrogen-bonding sites was expressed as the distances between the dummy atoms.
Similarly a distance map that describes the hydrogen-bonding sites on the receptor was prepared. Then the maps from the ligand were screened with the map from the receptor. In this study, we screened the ligand maps that found more than six matches of distances in the map from the receptor (Assumptions 13). According to the match in the distances, a model of -monoglycosylceramide could be positioned in the mCD1d (Fig. 2C
).
A large number of docking models of mCD1d/AGL517 and mCD1d/AGL563 were obtained. The models were screened by the following criteria: (i) the absence of unfavorable van der Waal's atomic contacts and (ii) the energy of interaction. For each of the seven conformations, 20 energetically favored models were selected. Then, Assumption 4 was applied to score the goodness of the docking models. Using mCD1d as the frame of reference, the docked models of AGL517 and AGL563 were compared for goodness of overlap of the 2''-OH and 4''-OH groups on the sugar moiety, and the 3-OH group on the sphingosine base expressed as r.m.s. fit values.
Figure 3(A) represents the schematic topology of the docking model. In this model, the fatty acyl chain stretched toward the A' pocket and the sphingosine base toward the F' pocket. The model (r.m.s. fit score 1.3A) was ranked fifth best. The top four models (r.m.s. fit scores 1.0, 1.1, 1.2 and 1.2A) were omitted from consideration, even though the important hydroxyl groups overlapped well for AGL517 and AGL563 because one or both of the alkyl chains of the ligand was placed outside of the binding groove (Assumption 5).
|
The model also suggests that the amide group on the fatty acyl chain of -GalCer interacts with Asp153. Asp153 is conserved in both hCD1d and mCD1d, but is replaced by Asn (hCD1a) or Tyr (hCD1b and hCD1c) in other species, again indicating the importance of Asp153 for the
-GalCer interaction. The 3-OH group on the sphingosine base, which is essential for V
14 NKT cell activation (21), resides between the groove helices, suggesting that this hydroxyl group interacts with a backbone carbonyl group (Val149) on the
2-helix of mCD1d (Fig. 3B
).
The final model of -GalCer (KRN7000)/mCD1d was subjected to a structure optimization calculation using Merck molecular force field (3135) and atomic charge parameters employing a dielectric constant of 4. For the important hydrogen-bonding pair atoms, the distance constraint energy term, Edist_c = k(d d0)2, was added where d is the distance between the two atoms, d0 = 2.8 Å, and k, the force constant, was set to 4 (kcal/mol/Å2). Structural optimization was carried out until a minimum energy change of 0.05 kcal/mol was attained. No significant change in the overall structure was observed after optimization, supporting the docking model as being energetically acceptable.
Functional activity of mutant mCD1d.
According to the suggestions obtained from the molecular modeling, we established a panel of transfectants expressing mutant mCD1d molecules with alanine substitutions. RMA-S cells were used as a host cell line, since they express marginal levels of mCD1d (Fig. 4A) and undetectable levels of MHC class I (data not shown). The mutations covered amino acid residues Arg79, Asp80, Glu83 (
1-helix) and Asp153 (
2-helix) of mCD1d, all of which were suggested by molecular modeling to be important for the interaction with
-GalCer. The amino acid residues around the four residues (
1-helix: 75, 76, 77, 78, 81, 82, 84 and 85, and
2-helix: 151, 154 and 155), and nearby charged amino acid residues (
1-helix: 74 and 86, and
2-helix: 148 and 166) were replaced by alanine. The mutation sites are indicated in Fig. 4
(A).
|
In order to characterize the effect of the mutations in the direct interaction with the NKT antigen receptor, the mCD1d mutants were tested for their ability to activate a V14 NKT cell clone 24.8.A1 which is activated by mCD1d in the absence of
-GalCer (28). Endogenous phosphatidylinositol is suggested to be an inherent antigen that the 24.8.A1 NKT cell recognizes (28), while it is not formally proved. Since the 24.8A1 NKT cell clone is an autoreactive clone, it is thus likely to assume that the reactivity of the clone reflects on its NKT antigen receptor binding site on the CD1d molecule if endogenous and exogenous ligands behave in a similar manner. Among the four critical residues, Asp80 and Asp153 locate inside the binding groove of mCD1d, indicating the difficulty in the direct interaction of the NKT cell receptor with these residues (Fig. 3B
). In contrast, the side chains of Arg79 and Glu83 are exposed outside the
-helix of mCD1d, suggesting possible contact sites with the NKT cell receptor. We, thus, chose R79A and E83A mutants for analysis. As shown in Fig. 5
, the R79A mutant successfully activated the 24.8.A1 NKT cell clone, while the E83A did not, indicating that at least Arg79 does not interact with the NKT cell receptor directly, but possibly with the 2''-OH of the carbohydrate moiety as suggested by the data in Fig. 3
(B). The control mutation of Gln154 that also locates outside the helix, however, does not influence the ability to stimulate the clone.
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The docking model suggests that Asp80 interacts with the 2''-OH on the carbohydrate moiety, whereas the amide moiety of the acyl chain interacts with Asp153 and also possibly with Asp80. Thus, the Asp80 and Asp153 residues would be covered by the ligand and not be accessible from the molecular surface of the mCD1d-GalCer complex, suggesting that these amino acids are responsible for
-GalCer interaction rather than for direct contact with the NKT cell receptor. This notion is also supported by the fact that Asp80 is common to both mCD1d and hCD1d, but is replaced by Gly (hCD1a) or Glu (hCD1b and hCD1c) in other CD1 molecules having no
-GalCer-presenting activity to V
14 NKT cells (15).
Based on the topological point of view, Arg79 and Glu83 are able to interact with the NKT cell receptor. However, Arg79 is essential for the -GalCer interaction. This is because the R79A mutant mCD1d transfectant successfully stimulated the 24.8.A1 NKT cell clone (Fig. 5
) which is stimulated by the recognition of endogenous phosphatidylinositol in the absence of
-GalCer (28). Distinct from Arg79, the E83A mutation, however, failed to stimulate the 24.8.A1 NKT cell clone (Fig. 5
). A simple interpretation is that Glu83 is the contact site for the NKT cell receptor rather than for
-GalCer binding. However, it is possible that Glu83 is important for the binding of endogenous phosphatidylinositol to mCD1d. Preferably, Glu83 is likely to interact with the 3''-OH of the carbohydrate moiety of
-GalCer as suggested by the docking model. In fact, an
-GalCer analogue that carries an additional glycosylation at the 3'' position of
-GalCer, Galß13Gal
11'Cer, has been shown to be a potent antigen for the stimulation of V
14 NKT cells (11). Given that the Galß13Gal
11'Cer is presented in a similar manner, the existence of the bulky substitution at the 3''-OH might disturb the interaction of Glu83 with the NKT cell receptor. Taken collectively, the role of Glu83 remains unclear from the present study. We have to wait for the results of the crystallographic analysis to obtain the final conclusion.
In our current model, the 3-OH group on the sphingosine base of -GalCer, which is critical for the activation of V
14 NKT cells, may not interact with any of the four residues. Instead, it is likely that it interacts with a backbone carbonyl group (Val149) on the
2-helix of mCD1d. Under the assumptions made for the docking modeling and the results of the mutation experiments, we could exclude the possibility that the 3-OH of the sphingosine interacts with any of the four charged amino acid residues by the following calculations. First, the 3-OH is hypothesized to form a hydrogen bond with either Asp80 or Asp153. Search calculations are carried out to find suitable docking models that satisfy (i) the interaction of Arg79 and Glu83 with the ligand, and (ii) the occupancy of the hydrophobic pockets of mCD1 with the alkyl chains of the ligand. As a result, no model was found (data not shown), thus eliminating the possibility that the 3-OH interacts with Asp80 or Asp153. If we assume that the 3-OH interacts with either Arg79 or Glu83, which are located outside the binding groove, it is obviously impossible to satisfy Assumption 5. Based on the above estimations, the 3-OH on the sphingosine base is likely to interact with the backbone carbonyl group of Val149. However, the interaction between the 3-OH group of the sphingosine base and the backbone atoms of mCD1d cannot be demonstrated experimentally by mutation studies.
Studies using surface plasmon resonance have demonstrated that the affinities of both the mCD1d and hCD1d for -GalCer are in the 0.11 and 0.010.1 µM ranges respectively (18,19). Likewise, despite their inability to stimulate V
14 NKT cells, mCD1d and hCD1d can bind to non-stimulatory ß-GalCer, N-dipalmitoyl-L-
-phosphatidylethanolamine or gangliosides (18). Thus, CD1d appears to have an ability to bind a variety of lipid-containing antigens regardless of their stimulatory activities. Residues whose side-chain atoms might interact with the fatty acyl chain of
-GalCer include Trp63, Met69 and Phe70. Side-chain atoms of Leu84, Val149 and Leu150 interact with the sphingosine base. These residues are well conserved among both hCD1d and mCD1 groups (36). In contrast, the 4 amino acid residues important for
-GalCer binding are conserved only in CD1d, but not in other CD1 families of both human and mouse. The findings are in good agreement with the functional data that
-GalCer is presented by both human and mCD1d but not by other hCD1 family members (15,37,38).
The model is compared with a crystal structure of the TCRMHCpeptide complex (39). The position of the alkyl chain (fatty acid moiety) of -GalCer seems to correspond well with the backbone of the peptide antigen. The sugar moiety of
-GalCer resides well within the space between mCD1d and the NKT cell antigen receptor. The position of the sugar moiety is similar to the position of the peptide (Tyr8p) bound to the B7/HLA-A2 complex, suggesting that the sugar moiety is recognized by CDR3ß or CDR1ß of the Vß8.2 chain. Recently, it has been reported that a consensus motif of CDR3ß is preferentially used by human NKT cells after selection by
-GalCer (12). This seems to support the suggestion that the sugar moiety is recognized in part by the CDR3ß.
The 4''-OH and 6''-OH groups on the sugar moiety make no direct interaction with mCD1d, but might interact with the NKT cell antigen receptor. However it should be noted that our model remains hypothetical regarding the interaction with the NKT cell receptor, considering the diversity found in several MHCTCR complex structures determined by X-ray crystallography (40,41). Recently, the structural basis of mCD1d for antigen presentation has been reported (42), and it was concluded that some of the acidic and polar amino acids in the CDR3 region of the TCR ß chain could be involved in the formation of hydrogen bonds with the galactose moiety of the antigen. Taken together with the surface plasmon resonance results, the abrogation of the response by these mutations may be due to a decreased stability of the mCD1d-GalCer complex or to inappropriate binding orientation for V
14 NKT receptor recognition, rather than a simple failure in the binding of
-GalCer to mCD1d.
![]() |
Acknowledgments |
---|
![]() |
Abbreviations |
---|
APC antigen-presenting cell |
GalCer galactosylceramide |
GlcCer glucosylceramide |
hCD1d human CD1d |
mCD1d mouse CD1d |
![]() |
Notes |
---|
Transmitting editor: M. Miyasaka
Received 14 February 2001, accepted 22 March 2001.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|